SAREPTA THERAPEUTICS, INC. Share-based Payment Arrangement, Amount Capitalized
SAREPTA THERAPEUTICS, INC. (SRPT) reported Share-based Payment Arrangement, Amount Capitalized of -$3.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement
us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for the quarter ending 2026-06-30 was -$3.56M.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for the quarter ending 2026-03-31 was -$4.27M.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for the quarter ending 2025-12-31 was -$4.49M.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for the quarter ending 2025-09-30 was -$1.47M.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for fiscal 2025 was -$15.68M.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for fiscal 2024 was -$20.83M.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for fiscal 2023 was $0.00.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for fiscal 2022 was $0.00.
| Period end | Share-based Payment Arrangement, Amount Capitalized 3 month | Share-based Payment Arrangement, Amount Capitalized 6 month | Share-based Payment Arrangement, Amount Capitalized 9 month | Share-based Payment Arrangement, Amount Capitalized 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.56M 10-Q · filed 2026-08-05 | -$7.83M 10-Q · filed 2026-08-05 | -$12.32M derived: sum of 3 quarters · filed 2026-08-05 | -$13.79M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$4.27M 10-Q · filed 2026-05-06 | -$8.77M derived: sum of 2 quarters · filed 2026-05-06 | -$10.23M derived: sum of 3 quarters · filed 2026-05-06 | -$14.83M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$4.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$5.96M derived: sum of 2 quarters · filed 2026-03-02 | -$10.55M derived: sum of 3 quarters · filed 2026-08-05 | -$15.68M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$1.47M 10-Q · filed 2025-11-06 | -$6.06M derived: sum of 2 quarters · filed 2026-08-05 | -$11.19M 10-Q · filed 2025-11-06 | -$16.79M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$4.59M 10-Q · filed 2026-08-05 | -$9.72M 10-Q · filed 2026-08-05 | -$15.32M derived: sum of 3 quarters · filed 2026-08-05 | -$20.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$5.13M 10-Q · filed 2026-05-06 | -$10.73M derived: sum of 2 quarters · filed 2026-05-06 | -$16.28M derived: sum of 3 quarters · filed 2026-05-06 | -$21.45M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$5.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$11.15M derived: sum of 2 quarters · filed 2026-03-02 | -$16.32M derived: sum of 3 quarters · filed 2026-03-02 | -$20.83M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$5.55M 10-Q · filed 2025-11-06 | -$10.72M derived: sum of 2 quarters · filed 2025-11-06 | -$15.23M 10-Q · filed 2025-11-06 | -$15.23M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$5.17M 10-Q · filed 2025-08-06 | -$9.69M 10-Q · filed 2025-08-06 | -$9.69M derived: sum of 3 quarters · filed 2026-03-02 | -$9.69M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$4.51M 10-Q · filed 2025-05-06 | -$4.51M derived: sum of 2 quarters · filed 2026-03-02 | -$4.51M derived: sum of 3 quarters · filed 2026-03-02 | -$4.51M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-01 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |